Prudential PLC Takes $356,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Prudential PLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 29,151 shares of the company’s stock, valued at approximately $356,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Raymond James & Associates grew its position in Elanco Animal Health by 1.3% during the fourth quarter. Raymond James & Associates now owns 70,130 shares of the company’s stock valued at $857,000 after acquiring an additional 895 shares during the period. Skandinaviska Enskilda Banken AB publ grew its position in Elanco Animal Health by 10.8% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 85,795 shares of the company’s stock valued at $1,048,000 after acquiring an additional 8,358 shares during the period. Van ECK Associates Corp grew its position in Elanco Animal Health by 15.1% during the fourth quarter. Van ECK Associates Corp now owns 1,657,541 shares of the company’s stock valued at $20,255,000 after acquiring an additional 217,344 shares during the period. California Public Employees Retirement System grew its position in Elanco Animal Health by 0.4% during the fourth quarter. California Public Employees Retirement System now owns 1,009,403 shares of the company’s stock valued at $12,335,000 after acquiring an additional 3,837 shares during the period. Finally, John G Ullman & Associates Inc. purchased a new stake in Elanco Animal Health during the fourth quarter valued at about $153,000.

Insider Buying and Selling

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 15,000 shares of the business’s stock in a transaction that occurred on Friday, March 10th. The shares were acquired at an average price of $9.60 per share, for a total transaction of $144,000.00. Following the completion of the purchase, the chief executive officer now owns 45,000 shares in the company, valued at approximately $432,000. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Jeffrey N. Simmons acquired 15,000 shares of Elanco Animal Health stock in a transaction that occurred on Friday, March 10th. The shares were purchased at an average cost of $9.60 per share, for a total transaction of $144,000.00. Following the completion of the purchase, the chief executive officer now directly owns 45,000 shares of the company’s stock, valued at approximately $432,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director R David Hoover acquired 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Friday, March 3rd. The shares were purchased at an average price of $11.13 per share, for a total transaction of $111,300.00. Following the completion of the purchase, the director now directly owns 155,000 shares of the company’s stock, valued at $1,725,150. The disclosure for this purchase can be found here. Insiders own 0.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ELAN. Morgan Stanley lowered their price target on Elanco Animal Health from $20.00 to $19.00 and set an “equal weight” rating for the company in a research report on Monday, January 30th. Barclays upgraded Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $14.00 price objective on the stock in a research note on Thursday, April 20th. Finally, Piper Sandler reduced their price objective on Elanco Animal Health from $15.00 to $12.00 in a research note on Thursday, March 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $16.50.

Elanco Animal Health Trading Up 0.6 %

NYSE:ELAN opened at $8.70 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.24 and a current ratio of 2.25. Elanco Animal Health Incorporated has a one year low of $8.48 and a one year high of $24.93. The business’s 50-day simple moving average is $9.22 and its 200 day simple moving average is $11.42. The stock has a market cap of $4.29 billion, a price-to-earnings ratio of -217.45, a price-to-earnings-growth ratio of 6.03 and a beta of 0.92.

Elanco Animal Health (NYSE:ELAN – Get Rating) last released its quarterly earnings results on Tuesday, May 9th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.29 by $0.16. Elanco Animal Health had a positive return on equity of 8.21% and a negative net margin of 0.49%. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the previous year, the firm posted $0.36 earnings per share. The company’s revenue was up 2.5% compared to the same quarter last year. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.8 earnings per share for the current fiscal year.

Elanco Animal Health Profile

(Get Rating)

Elanco Animal Health, Inc innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.